TABLE 1.
Baseline demographic, clinical, and clinicopathologic data for 39 dogs comprising the intention‐to‐treat population
| Variable | Enalapril group | Telmisartan group |
|---|---|---|
| Number in the intention‐to‐treat | 19 | 20 |
| Age (years) | 10.4 (3.1‐14.5) | 8.8 (4.3‐14.9) |
| Sex (n) | ||
| Female spayed | 13 | 14 |
| Male neutered | 6 | 6 |
| Body weight (kg) | 13.4 (3.5‐41.3) | 11.5 (4‐42.8) |
| Breed (n) | ||
| Jack Russell terrier | 4 | 0 |
| Beagle | 2 | 2 |
| Miniature Schnauzer | 0 | 2 |
| Boston terrier | 0 | 2 |
| Golden retriever | 2 | 0 |
| Fox terrier | 0 | 2 |
| Yorkshire terrier | 2 | 0 |
| Other (n < 2) | 8 | 9 |
| Mixed breed | 1 | 3 |
| Systolic arterial blood pressure (mm Hg) | 154 (126‐210) | 154 (120‐220) |
| Blood creatinine concentration (mg/dL) | 0.9 (0.5‐5.5) | 0.9 (0.7‐5.0) |
| Blood urea nitrogen concentration (mg/dL) a | 11 (8‐101) | 13 (5‐64) |
| Blood potassium concentration (mmol/L) | 4.32 (3.89‐5.5) | 4.39 (3.88‐4.88) |
| Serum albumin concentration (g/dL) b | 3.4 (1.7‐3.9) | 3.3 (2.2‐3.9) |
| Hematocrit (%) | 45 (35‐53) | 46 (29‐53) |
| Urinary protein‐to‐creatinine ratio c | 2.29 (0.91‐15.54) | 4.65 (0.90‐13.39) |
| Study group (n) | ||
| Nonazotemic, normotensive | 6 | 6 |
| Nonazotemic, hypertensive | 9 | 8 |
| Azotemic, normotensive | 1 | 2 |
| Azotemic, hypertensive | 3 | 4 |
| IRIS CKD stage (n) | ||
| 1 | 15 | 14 |
| 2 | 1 | 3 |
| 3 | 2 | 3 |
| 4 | 1 | 0 |
Note: Data are presented as median (range) where appropriate. azotemic, blood creatinine concentration (Cr) ≥1.4 mg/dL; hypertensive, average systolic blood pressure ≥150 mm Hg.
Abbreviations: CKD, chronic kidney disease; IRIS, International Renal Interest Society.
For one dog, blood urea nitrogen concentration was greater than the upper limit of reporting for the assay (100 mg/dL) and was assigned a value of 101 mg/dL.
Baseline albumin was measured in only n = 17 enalapril‐ and n = 14 telmisartan‐treated dogs.
Baseline urinary protein‐to‐creatinine ratio (UPC) is presented as the average of two measurements, one obtained on study day 0, and the other obtained within the 30 days preceding enrollment for n = 10 enalapril‐ and n = 9 telmisartan‐treated dogs. For all other dogs, the UPC measured at day 0 is used for the baseline value.